Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05985824
Other study ID # SANKOU-HEM-ZD-01
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 6, 2023
Est. completion date October 30, 2023

Study information

Verified date August 2023
Source Sanko University
Contact Zeynep DOGAN, Master
Phone +905074274985
Email zeynep.dogan@sanko.edu.tr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This research is a randomized controlled experimental study to determine the effect of pranayama breathing exercise applied to patients with lung cancer on quality of life.


Description:

The population of the study consists of patients with primary diagnosis of lung cancer who applied to Erciyes University Health Practice and Research Center Nazende-Nuri Ă–zkaya Oncology Day Treatment Center. Patients with primary diagnosis of lung cancer who met the inclusion criteria of the study and volunteered to participate in the study will constitute the sample of the study. It was calculated by performing power analysis for the sample of the study. In the power analysis made according to the effect size of the research; When calculating the partial eta square effect size of 0.06, alpha=0.05 and power=0.80 for two-way ANOVA in repeated measurements, the sample size per group is 35. A total of 70 people will be sampled. Data Collection Form and Tools: The data of the study are collected through Personal Information Form, European Cancer Research and Treatment Organization Quality of Life Scale 3rd Version, Informed Voluntary Consent Form, Eastern Cooperative Oncology Group (ECOG) Performance Scale, Mini Mental Test forms. The data of the research were obtained from the academic committee, ethics committee and institution of Erciyes University Faculty of Health Sciences. Patients who accept the study are pre-tested. Patient selection for the intervention and control groups of the study is made using the minimization randomization method. In the minimization method, the patients are assigned to groups according to age, gender, cancer cell type, cancer stage, duration and having a chronic disease. Data are collected from lung cancer patients who accepted to participate in the study, who applied to the outpatient chemotherapy unit by using face-to-face interview method by the researcher herself. During the study, the routine treatments of the patients in the intervention and control groups will not be interfered with. Pre-Test: The patients with lung cancer who applied to the outpatient chemotherapy unit are informed about the research by the researcher and after obtaining the consent form, the personal information form and the quality of life scale are applied to the intervention and control groups by using the face-to-face interview method and the records obtained from the patient files, respectively. Applications to the Intervention Group: Among the pranayama breathing exercises, only the Nadi Shothana technique will be applied to lung cancer patients who apply to the outpatient chemotherapy unit. This exercise will be done every day for 4 weeks, covering 15-20 minutes. After applying the personal information form and quality of life scale to the patients, the researcher will be informed about what the pranayama exercise is, its importance, purpose and benefits. Patients will be given an application guide and their questions will be answered if they have any. In patient education, the pranayama breathing exercise will be applied face-to-face by the researcher on the first day of chemotherapy treatment, before drug treatment. The application steps will be repeated until the patient learns, both by explaining and showing the patient, and if there are points that the patient cannot do, they will be corrected. When the patients are observed to perform the application fully and the chemotherapy treatments are finished, they will be asked to do the pranayama breathing exercise every day for 4 weeks, and with the same researcher 3 days a week (Monday, Wednesday, Saturday) with a smart phone whatsapp video call, the effectiveness and continuity of the application will be ensured and the patients will be monitored. If the patients assigned to the intervention group are unable to perform the application or have difficulties, the study with these patients will be terminated. Applications to the Control Group: After the application of the personal information form and the quality of life scale, no breathing exercises will be performed. Individuals will continue their daily lives. After 4 weeks, the quality of life scale will be administered again. After the implementation of the quality of life scale, pranayama breathing exercise training will be given to all control group patients and they will be applied for 2 sessions. Post-Test: The quality of life scale will be re-administered to the patients in both groups by the same researcher 4 weeks after the pre-test, and one day after the pranayama breathing exercise application to the control group and intervention group.


Recruitment information / eligibility

Status Recruiting
Enrollment 70
Est. completion date October 30, 2023
Est. primary completion date October 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Over 18 years old, 2. Lung Cancer Stage III and IV, 3. Being literate, 4. Having sufficient communication skills, 5. Does not have any ailment that will reduce the ability to comprehend and understand, 6. Agreeing to participate in the research, 7. Knowing the diagnosis, 8. Receiving chemotherapy treatment, 9. ECOG performance score = 2, 10. Not using opioids or sedating drugs, 11. Patients who can use smart phones themselves or their relatives will be included in the study Exclusion Criteria: 1. Lung Cancer I., II., stage, 2. Receiving radiotherapy, 3. Having a history of Brain Metastasis, 4. Using integrated health practices in the treatment process, 5. Those who exercise regularly 6. For patients over 65 years of age, patients with a score below 24 on the mini mental test were not included in the study. Research Termination Criteria Intervention Group 1. Developing additional health problems, 2. Unwilling to continue the practice of pranayama breathing exercise, 3. Those who lost their lives during the research process, 4. Those who do not practice pranayama breathing exercise as recommended or cannot do it effectively, 5. The study will be terminated with patients who want to withdraw from the study. Control Group 1. Developing additional health problems, 2. Those who lost their lives during the research process, 3. The study will be terminated with patients who want to withdraw from the study.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Pranayama breathing exercise
Pranayama is an important step in yoga, way of life, and is translated as "the science of breathing, breath control, willful breathing". This alternating breathing-out action also balances the sympathetic and parasympathetic nervous systems, giving the person a state of calm, providing relaxation and positively affecting fatigue. Application steps; Right hand Nasika mudra is performed. Nasika mudra is the mudra where the second and third fingers of the right hand are folded into the palm and the other fingers are exposed. Then the right nostril is closed with the first finger of the right hand. Start by breathing through the left nostril. Then the left nostril is closed with the fourth finger and the breath is held. While the left nostril is closed, the right nostril is opened and inhaled. Breathe again through

Locations

Country Name City State
Turkey Erciyes University Kayseri Talas

Sponsors (1)

Lead Sponsor Collaborator
Sanko University

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Quality of life of lung cancer patients European Organization for Cancer Research and Treatment Quality of Life Scale :measure lung cancer patients before and four weeks aftter. European Organization for Cancer Research and Treatment Quality of Life Scale: scale consists of 3 sub-titles: general well-being, functional area and symptom control. While the maximum score that patients will get from these three sub-headings is 100, the minimum score is 0. The first 28 questions are questions related to the functional area and symptom control subheadings, and low scores on these questions mean high quality of life, and high scores mean low quality of life. The last two questions belong to the sub-heading of general well-being, and a low score on these questions indicates a low quality of life, and a high score indicates a high quality of life. four weeks
See also
  Status Clinical Trial Phase
Completed NCT03918538 - A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors N/A
Recruiting NCT05078918 - Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors N/A
Active, not recruiting NCT04548830 - Safety of Lung Cryobiopsy in People With Cancer Phase 2
Completed NCT04633850 - Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05583916 - Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05898594 - Lung Cancer Screening in High-risk Black Women N/A
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03575793 - A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer Phase 1/Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Terminated NCT01624090 - Mithramycin for Lung, Esophagus, and Other Chest Cancers Phase 2
Terminated NCT03275688 - NanoSpectrometer Biomarker Discovery and Confirmation Study
Not yet recruiting NCT04931420 - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Phase 2
Recruiting NCT06052449 - Assessing Social Determinants of Health to Increase Cancer Screening N/A
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Not yet recruiting NCT06017271 - Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
Recruiting NCT05787522 - Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk